Cadila Healthcare - ZyCoV-D Vaccine Nod In Increasingly Competitive Domestic Market: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Cadila Healthcare Ltd.’s Covid-19 vaccine ZyCoV-D received emergency user approval from Drugs Controller General of India which is world’s first ever ‘plasmid DNA’ based three-dose vaccine with needle-free/painless delivery.
Cadila Healthcare conducted phase-III clinical trial of the vaccine on 28,000 volunteers, including 1400 subjects in the age group of 12-17 age group.
With favorable and acceptable safety profile, the approval was unique as it allows ZyCoV-D to be administered (first time in India) with adolescent age group (12-17 yrs) along with adult population (18 yrs and above).
The company also applied for two-dose vaccine which may take another one to two months for expert group of DCGI to evaluate its efficacy profile data.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.